Author: Wu Liu; Mehmet U. Caglar; Zhangming Mao; Andrew Woodman; Jamie J. Arnold; Claus O. Wilke; Craig E. Cameron
Title: More than efficacy revealed by single-cell analysis of antiviral therapeutics Document date: 2019_4_12
ID: aiyg061l_22
Snippet: of three classes of anti-PV drugs revealed three unique signatures based on changes to the 242 phenomenological parameters used to describe infection dynamics. We reasoned that PCA might 243 provide an even more robust approach to compare datasets using our five parameters. As shown 244 in Fig. 5 , PCA resolves each class of inhibitor from the other, as well as from outcomes in the 245 absence of drug. Importantly, the mechanistically related but.....
Document: of three classes of anti-PV drugs revealed three unique signatures based on changes to the 242 phenomenological parameters used to describe infection dynamics. We reasoned that PCA might 243 provide an even more robust approach to compare datasets using our five parameters. As shown 244 in Fig. 5 , PCA resolves each class of inhibitor from the other, as well as from outcomes in the 245 absence of drug. Importantly, the mechanistically related but chemically distinct inhibitors of 246 HSP90 cluster by PCA (see GA and GS in Fig. 5) . We conclude that single-cell analysis of 247 antiviral therapeutics can provide not only information on the efficacy of a drug but also 248 information on the mechanism of action. This experimental paradigm should have a 249 transformative impact on the drug-development process. 250
Search related documents:
Co phrase search for related documents- action mechanism and drug development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- action mechanism and drug development process: 1, 2, 3, 4, 5
- action mechanism and drug efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- action mechanism and experimental paradigm: 1, 2
- action mechanism and infection dynamic: 1
- action mechanism and inhibitor class: 1, 2, 3, 4
- antiviral therapeutic and drug development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- antiviral therapeutic and drug development process: 1
- antiviral therapeutic and drug efficacy: 1, 2, 3, 4
- antiviral therapeutic and inhibitor class: 1
- drug development and experimental paradigm: 1
- drug development and infection dynamic: 1, 2, 3
- drug development and inhibitor class: 1
- drug development process and experimental paradigm: 1
- drug efficacy and infection dynamic: 1
- drug efficacy and inhibitor class: 1
Co phrase search for related documents, hyperlinks ordered by date